← All trials
NCT06031558
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2023
- Primary completion
- Sep 20, 2024
- Completion date
- Jun 20, 2026
- First posted
- Sep 11, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Government of ChinaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.